Search our library
Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process (ASM/ESCMID 2019)
Alternatives to (classical) antibiotics: what will it take to convincingly develop a virulence inhibitor or similar indirect agent?
Decisions, Decisions: What Makes a Good Hit? A Good Lead? Why Do You Write a TPP? How Do You Write a TPP?
How Does a Molecule Become a Physical Medicine to be Given to a Human: The Importance of Chemistry, Manufacturing, and Controls
The challenges and opportunities for antimicrobial R&D in low- and middle-income countries – India case study
Find out how GARDP is redoubling its efforts to accelerate the development and delivery of new and improved antibiotics.
Clinical development for non-developers Part 3: Antibacterial Drug Enhancer Combinations and Non-traditional Products
Clinical development for non-developers, part 2: Development of antibacterial drugs targeting specific pathogens
Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B